Trastuzumab Deruxtecan and Pembrolizumab for Non-Small Cell Lung Cancer: Study Participation Information

ClinicalTrials.gov identifier: NCT06899126

This Phase 3 clinical study compares trastuzumab deruxtecan plus pembrolizumab with platinum-based chemotherapy plus pembrolizumab as first-line treatment for eligible HER2-overexpressing, PD-L1-low non-squamous non-small cell lung cancer.

Study availability and enrollment status may change. A California Research Institute coordinator can confirm current local availability and explain the screening process.

Request study information